Research Article

Efficacy and Safety of Yokukansan in Treatment-Resistant Schizophrenia: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial

Table 5

The presentation of percentage PANSS-derived responder rates (per-protocol set and intention-to-treat).

PANSSTotal <25% PANSS25–49% PANSS50–74% PANSS75–100% PANSS
Reduction (%)Reduction (%)Reduction (%)Reduction (%)

PPS
 TJ-54 group4828 (58.3)15 (31.3)4 (8.3)1 (2.1)
 Placebo group5040 (80.0)8 (16.0)2 (4.0)0 (0)
ITT
 TJ-54 group5429 (53.7)18 (33.3)6 (11.1)1 (1.8)
 Placebo group6044 (73.3)12 (20.0)4 (6.7)0 (0)

There was no statistical significant difference. PPS: per-protocol set; ITT: intention-to-treat.